EQHIGH SIGNALOPERATIONAL10-K

EQ has undergone a complete strategic pivot, abandoning its previous clinical-stage itolizumab program to focus on preclinical aryl hydrocarbon receptor modulator EQ504 for autoimmune disorders.

This represents a fundamental transformation of the company's therapeutic focus and development timeline, effectively resetting the investment thesis. The removal of going-concern language and strengthened balance sheet suggests successful fundraising has enabled this strategic shift, but investors now face a much earlier-stage risk profile with EQ504 still in preclinical development compared to the previous clinical-stage assets.

Comparing 2026-03-25 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows meaningful improvement in liquidity and capital structure, with cash substantially higher at $30.3M and current liabilities reduced by roughly half to $2.9M. Stockholders' equity grew to $28.6M while total debt declined modestly, indicating likely equity fundraising that has strengthened the balance sheet. However, operating cash burn worsened to -$22.7M, reflecting the ongoing cash requirements of this loss-making biotechnology operation as it pursues its new strategic direction.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+67.4%
$18.1M→$30.3M

Cash position surged 67.4% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
-53.8%
$6.4M→$2.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Stockholders Equity
Balance Sheet
+50%
$19.1M→$28.6M

Equity base grew 50% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Liabilities
Balance Sheet
-49.7%
$6.5M→$3.3M

Liabilities reduced 49.7% — deleveraging improves balance sheet strength and financial flexibility.

Capital Expenditure
Cash Flow
-43.5%
$85K→$48K

Capex reduced 43.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
+24.5%
$25.6M→$31.9M

Asset base grew 24.5% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+24.3%
$25.0M→$31.0M

Current assets grew 24.3% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
-19.6%
-$19.0M→-$22.7M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Revenue
P&L
+13.9%
$36.1M→$41.1M

Revenue growing 13.9% — solid top-line momentum, watch margins for quality of growth.

Total Debt
Balance Sheet
-10.9%
$10.2M→$9.1M

Debt reduced 10.9% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-27
ADDED
As of March 20, 2026, there were 63,226,556 shares of the registrant s common stock outstanding.
We have incurred significant losses since our inception, expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability; We will require substantial additional funding to complete the planned or future development and any commercialization of EQ504, EQ302 and any future product candidates.
Overview We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients.
Our primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development.
EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial impact inducing anti-inflammatory cells and cytokines while reducing proinflammatory cells and cytokines and improving intestinal tissue barrier function and repair.
+7 more — sign up free →
REMOVED
As of March 20, 2025, there were 35,609,907 shares of the registrant s common stock outstanding.
We have incurred significant losses since our inception, expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability; Our need for additional capital raises substantial doubt about our ability to continue as a going concern.
We will require substantial additional funding to complete the development and any commercialization of itolizumab (EQ001) and EQ302, if we resume development activities, and any future product candidates.
If CMOs, including Biocon, our exclusive CMO for itolizumab (EQ001), encounter such difficulties, our ability to provide supply of our product candidates for clinical studies, our ability to obtain marketing approval, or our ability to obtain commercial supply of our products, if approved, could be delayed or stopped; We rely, and intend to continue to rely, on CROs to conduct our clinical studies and perform some of our research and preclinical studies.
Overview We are a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →